2. Metabolic Enzyme/Protease
  3. Aminotransferases (Transaminases)
  4. ERG245

ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC50 of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

ERG245

ERG245 構造式

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 165 在庫あり
Solution
10 mM * 1 mL in DMSO USD 165 在庫あり
Solid
5 mg $150 在庫あり
10 mg $240 在庫あり
25 mg $480 在庫あり
50 mg $765 在庫あり
100 mg $1220 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

ERG245 関連抗体

Top Publications Citing Use of Products

Aminotransferases (Transaminases) アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
GPT/ALT GOT/AST

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

ERG245 is a selective amino acid aminotransferase (BCAT1) inhibitor with a human IC50 of 0.5 nM. ERG245 enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245 shows anti-inflammatory and anti-tumor activities. ERG245 can be used for the researches of cancer anf inflammation, such as colitis and colon cancer[1].

IC50 & Target[1]

BCAT1

0.5 nM (IC50)

体外実験

ERG245 (0.1-10 nM; 10 min) potently and selectively inhibits recombinant human BCAT1 with an IC50 of ~0.5 nM, while showing minimal activity against recombinant human BCAT2[1].
ERG245 (200 μM) reduces IFNγ and granzyme B production in activated human CD8+ T cells from donors[1].
ERG245 (100 μM; 72-96 h) partially inhibits the proliferation of activated human CD8+ T cells, as measured by reduced Weighted Proliferation Index[1].
ERG245 (100 μM; 24 h) increases mitochondrial OXPHOS in activated human CD8+ T cells after 24 hours[1].
ERG245 (400 μM; 60 min) induces a rapid increase in mitochondrial iron levels in activated wild-type Jurkat cells[1].
ERG245 (200 μM) increases cytosolic aconitase 1 (ACO1) activity in activated human CD8+ T cells[1].
ERG245 (200 μM; 24 h) partially prevents the development of a terminally exhausted phenotype in human CD8+ T cells generated via repeated TGF-β-supplemented activation, reducing CD8+ PD-1+ TIM3+ GZMB+ cell frequency and CXCL13 secretion[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ERG245 関連抗体

Cell Proliferation Assay[1]

Cell Line: Human CD8+ (hCD8+) T cells
Concentration: 100 μM
Incubation Time: 72, 96 h
Result: Reduced the Weighted Proliferation Index of activated hCD8+ T cells significantly, indicating partial inhibition of cell expansion.
体内実験

ERG245 (5 mg/kg; i.p.; twice daily; 6 days) suppresses CD8+ T cell activation and mitigates disease activity in a murine DSS (HY-116282C)-induced colitis model[1].
ERG245 (5 mg/kg; i.p.; twice daily on days 0, 1, and 2) combined with anti-PD-1 induces complete, durable tumor regressions in 83% of mice in the CT26 syngeneic colon cancer model and enhances the frequency of cytotoxic CD8+ T cells in the CT26 tumor microenvironment[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (female, 18-20 g, acute Dextran sulfate sodium-induced colitis)[1]
Dosage: 5 mg/kg
Administration: i.p.; twice daily; 6 days
Result: Reduced colon mass/length ratio.
Decreased the frequency of activated CD8+ CD25+ T cells in mesenteric lymph nodes.
Animal Model: Balb/c (female, 6-7 weeks old, syngeneic CT26 colorectal cancer)[1]
Dosage: 5 mg/kg (ERG245); 10 mg/kg (anti-PD-1)
Administration: i.p.; twice daily on days 0, 1, and 2 (ERG245); i.p.; on days 0, 4, 7, and 11 (anti-PD-1)
Result: Did not alter tumor growth kinetics or survival as monotherapy.
Resulted in 83% (5/6) complete tumor regression rate when combined with anti-PD-1, compared to 17% (1/6) with anti-PD-1 monotherapy.
Prevented tumor growth after re-inoculation in mice with complete tumor regression, indicating immunological memory.
分子量

347.20

分子式

C17H15BrO3
Appearance

Solid

Color

White to off-white

SMILES

OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (288.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8802 mL 14.4009 mL 28.8018 mL
5 mM 0.5760 mL 2.8802 mL 5.7604 mL
10 mM 0.2880 mL 1.4401 mL 2.8802 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8802 mL 14.4009 mL 28.8018 mL 72.0046 mL
5 mM 0.5760 mL 2.8802 mL 5.7604 mL 14.4009 mL
10 mM 0.2880 mL 1.4401 mL 2.8802 mL 7.2005 mL
15 mM 0.1920 mL 0.9601 mL 1.9201 mL 4.8003 mL
20 mM 0.1440 mL 0.7200 mL 1.4401 mL 3.6002 mL
25 mM 0.1152 mL 0.5760 mL 1.1521 mL 2.8802 mL
30 mM 0.0960 mL 0.4800 mL 0.9601 mL 2.4002 mL
40 mM 0.0720 mL 0.3600 mL 0.7200 mL 1.8001 mL
50 mM 0.0576 mL 0.2880 mL 0.5760 mL 1.4401 mL
60 mM 0.0480 mL 0.2400 mL 0.4800 mL 1.2001 mL
80 mM 0.0360 mL 0.1800 mL 0.3600 mL 0.9001 mL
100 mM 0.0288 mL 0.1440 mL 0.2880 mL 0.7200 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ERG245 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ERG245ERG 245ERG-245Aminotransferases (Transaminases)CD8+ T cellsBCAT1BCAT2Jurkat cellsanti-PD-1murine tumor modelscolon cancerTGF-βOXPHOSCT26Inhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
ERG245
製品番号:
HY-159730
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.